Brigham Young University Journal of Public Law
Volume 8
Issue 1
Family Structure at the End of the Twentieth Century

Article 11

5-1-1993

Fetal Tissue Transplants as Treatment for
Parkinsonian Patients: A Miracle Cure or Science
Fiction Nightmare?
Billye D. Baird

Follow this and additional works at: https://digitalcommons.law.byu.edu/jpl
Part of the Medical Jurisprudence Commons
Recommended Citation
Billye D. Baird, Fetal Tissue Transplants as Treatment for Parkinsonian Patients: A Miracle Cure or Science Fiction Nightmare?, 8 BYU J.
Pub. L. 173 (1993).
Available at: https://digitalcommons.law.byu.edu/jpl/vol8/iss1/11

This Comment is brought to you for free and open access by BYU Law Digital Commons. It has been accepted for inclusion in Brigham Young
University Journal of Public Law by an authorized editor of BYU Law Digital Commons. For more information, please contact
hunterlawlibrary@byu.edu.

Fetal Tissue Transplants as Treatment for
Parkinsonian Patients: A Miracle Cure or
Science Fiction Nightmare?
An old film portrays the story of a woman who had been
severely injured in an automobile accident. A scientist, motivated by his love for the injured woman and his desire to simultaneously further science, took the woman's decapitated head and
miraculously preserved it so that it functioned perfectly in a
fluid-filled tray.
The rest of the woman's body was combined with remnants
of other victims to make a "person". The "person" turned out to
be a mindless monster capable only of destruction. The unfortunate head, while totally capable of reason and fully appreciative of what her scientist fiance had done, wanted only to be
allowed to die.
Today, the movie is science fiction. But what about tomorrow?
I.

INTRODUCTION

In March 1992, the House of Representatives passed and
sent the Public Health Service Act to the Senate. This bill
proposed to remove the moratorium placed on the National
Institute of Health which prohibited the federal funding of
research on fetal tissue obtained from induced abortions. 1
"Fetal" means in utero from three months until birth. 2
"Tissue" means a collection of similar cells. 3 Fetal tissue comes
from aborted fetuses. Many questions arise about these aborted
fetuses. Are parents asked if their aborted fetuses can be dissected? Do parents get paid for "goods" thus obtained? Is there
a "market" for fetal tissue? How does this relate to the abortion
issue?
What should an anti-abortion person think about this procedure? Can one justify elective abortion if it will alleviate a

1 The bill ultimately did not pass. President Bush would not sign it, and
Congress did not have the votes to override his veto. See infra part IV.A.
2 ILLUSTRATED STEDMAN'S MEDICAL DICTIONARY 521 (5th ed. 1982) (see "fetus").
3 ld. at 1456.
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living person's inevitable physical and mental anguish? Some
Christian beliefs suggest "no."4 The following is the result of
my struggle to shed light on a personally clouded issue. 5
This article will review the etiology of Parkinson's Disease.
It will review the effectiveness of traditional Parkinson's Disease therapy and discuss the current areas being researched. It
will then analyze the arguments for and against the use of
fetal tissue research, in general, in relation to the moratorium;
and in treating Parkinson's Disease specifically. It will additionally demonstrate the availability of alternative areas of
research for treatment of Parkinson's Disease. Finally, the
Clinton Administration's policy on the use of fetal tissue will be
discussed.
II.

PARKINSON'S DISEASE

A. The Nature of Parkinson's Disease.
Parkinson's Disease (PD) is a chronic, progressive illness. 6
The actual cause of the disease is unknown. 7 In fact, the process of elimination is used more in PD diagnosis than in the
diagnosis of almost any other disease. 8
What physicians do know is that PD patients have a deficiency of special brain cells which produce a chemical called
dopamine. 9 Dopamine aids the passage of stimuli and responses to and from the brain. 10 Without this chemical, neural
transmissions are terminated or impaired, causing the typical
PD patient to have uncontrollable tremors of the limbs or the
head; a loss of balance; a temporary, involuntary inability to

4 "For a good tree bringeth not forth corrupt fruit; neither doth a corrupt
tree bring forth good fruit." Luke 6:43.
5 My mother, Liddy Bankston Baird, was diagnosed with Parkinson's Disease in March of 1992. This article is dedicated to her.
6 A.N. Lieberman et a!., Parkinson's Disease Handbook: A Guide for Patients and Their Families.
7 ld. at 2.
8 ld. at 2, 11-13.
9 This deficiency is caused by the death of these specialized cells. What
causes this cellular death is unknown though current speculations include genetic
susceptibility; environmental toxins (see William C. Scott & Russell H. Patterson,
Council on Scientific Affairs and Council on Ethical and Judicial Affairs, Medical
Applications o( Fetal Tissue Transplant, 263 JAMA 565 (1990)); human chemical
production abnormalities; and viral infections. It is known that many victims of a
world wide epidemic of viral encephalitis (between 1918 and 1932) developed PD.
10 Lieberman et a!., supra note 6, at 3.
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move; a poor or stooped posture; and/or a slow, shuffling step
when walking. 11 The level of incapacity can range from mild
interference and annoying tremor, to total, bedridden dependence.12
B.

The Treatment of Parkinson's Disease

There is presently no cure for PD. 13 All treatments are
designed to ameliorate symptoms only. 14 The most commonly
used treatment is a progressively complex regime of medications meant to augment dopamine levels in the brain, and to
combat the many side effects of the medications themselves. 15
The numerous side effects along with the increasing and inevitable tolerance to PD medications 16 make alternate treatment
methods desirable.
The most recently researched treatment methods involve
transplantation of tissue into the brain. Two different types of
tissue have been used. The first type, used between 1987 and
1988, was tissue taken from the PD patient's own adrenal
gland (located above the kidneys) and transplanted into his
brain. 17 The second type of tissue used was fetal tissue. 18 Fetal tissue was (and still is) an attractive source of grafts for
scientists because it presents fewer of the complications associated with other types of transplants. 19

11 Other symptoms include drooling, forced eyelid closure, difficulty in swallowing, incontinence, impotence, sleep disturbances, senility, dementia, and speech
problems. Lieberman et al., supra note 6, at 5-10.
12 Lieberman et al., :-;upra note 6, at 14 (rating scale).
13 Lieberman et al., :-;upra note 6, at 16.
14 !d. at 16.
15 Levodopa (L-dopa) and L-dopa compounds are the most effective medications used to control PD symptoms. L-dopa side effects include hallucinations and
depression. Lieberman, supra note 6, at 19.
16 Lieberman et al., supra note 6, at 21.
17 Enrico Fazzini, A Comparison of Neurosurgical Procedures in the Treatment of Parkinson's Disease, AM. PARKINSON DISEASE Ass'N, Spring 1993, at 4.
18 The fetal tissue used in experimentation included fetal adrenal tissue and
fetal brain tissue. !d.
19 David R. Liskowsky, Neural Grafting: Repairing the Brain and Spinal
Cord, 265 JAMA 3225 (1991) (stating that an autograft (taking tissue from one
area of the PD patient for transplant into another area) put the PD patient at risk
of two very complex surgeries; transplants from non-fetal donors risk rejection of
the tissue; and genetically engineered (or cloned) cells are not yet scientifically
feasible). But see infra pp. 190-92.
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Foreign Fetal Tissue Transplantation in Treatment of
Parkinson's Disease

Because of the relative localization of the area of the brain
damaged, PD was selected as an ideal disorder for transplant
experimentation. 20 However, since implantation of adrenal
tissue had yielded only minimal, inconsistent and transitory
results, 21 in 1987 scientists turned their focus towards fetal
tissue implantation. 22
Scientists have found fetal tissue easier to work with because it has the unique ability to differentiate into the cell type
surrounding it. 23 This means that when fetal tissue is implanted in the brain it becomes brain cells like those into which
it was transplanted. Therefore, the likelihood of the PD
patient's body reacting to and rejecting the transplanted tissue
as "foreign" is lessened. 24
Mexico's Dr. Ignacio Madrazo was one of the first to do a
study comparing transplantation of fetal adrenal tissue with
fetal brain tissue. 25 According to Madrazo, the adrenal transplant patients showed an amelioration of rigidity of movement
but no other improvement in symptoms. 26 Drug therapy that
was initially lowered, required gradual increasing. 27 The recipients of the fetal brain tissue showed an amelioration of
more symptoms, and all were able to lessen medication levels.28
Although Madrazo called his results (after one year of
observation) "encouraging,"29 his factual findings and the resultant conclusions drawn have been questioned. 30 As Sarah

20
21
22
23
24
25
Adrenal
(1990).
26

Scott & Patterson, supra note 9, at 569.
Liskowsky, supra note 19, at 3225.
Fazzini, supra note 17, at 4.
Scott & Patterson, supra note 9, at 566.
ld.
Ignacio Madrazo et al., Fetal Homotransplants (Ventral Mesencephalon and
Tissue) to the Striatum of Parkinsonian Subjects, 47 ARCH. NEUROL. 1281

ld. at 1283.

27 ld.

28 ld.
29 ld. at 1284.
30 Thomas B. Freeman & G. Warren Olanow, Fetal Homotransplants in the
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Glazer reported in her article, The Fight over Fetal Tissue, 31
researchers found Madrazo's "results to be exaggerated, shortlived and accompanied by an unacceptable rate of complications."32
In 1991 an English study was done exclusively using fetal
brain tissue. 33 Although the English results were initially
more promising than Madrazo's, the long term effects (at the
end of one year) once again proved inconsistent and temporary.34

B.

The Use of Fetal Tissue in the United States

The use of fetal tissue began decades ago. In the 1950s,
human fetal kidney cells were used in the development of the
polio vaccine. 35 Fetal thymus transplantation was also used in
the treatment research for DiGeorge's Syndrome. 36
Since the 1950s, fetal tissue grafting research has been
done in animals for many disorders, including the neurological
disorders of Huntington's Disease, Alzheimer's Disease, and
motor neuron disease. 37 Research done on animals has also
been done on spinal cord injuries, brain disorders, epilepsy,
diabetes, multiple sclerosis, the mechanisms of viral infections,
the diagnosis of viral infections, and detecting markers for

Treatment of Parkinson's Disease, 48 ARCH. NEUROL. 900 (1991). According to Freeman, the best period for neuronal development before axonal extension is 6.5 to 8.0
weeks gestation. All of Madrazo's fetuses were older than that. He also argued,
among other things, that the initial improvement of the patients occurred too
quickly to be the results of neuronal outgrowth of dopaminergic neurons. Id. at
901.
.31 Sarah Glazer, The FiRht over Fetal Tissue, WASH. POST, June .30, 1992, at
Z10 .
.32 Id .
.3.3 Bruce T. Henderson et al., Implantation of Human Fetal Ventral Mesencephalon to the Right Caudate Nucleus in Advanced Parkinson's Disease, 48 ARCH.
NEUROL. 822 (1991) .
.34 Id. at 825 .
.35 Henry L. Nadler, Fetal Tissue Transplantation, 14.3 AM. J. Dis. CHILD.
149 (1989). DiGeorge's Syndrome is a disease which develops in the embryonic

stages of development. The pharyngeal (throat) region fails to develop into the
thymus gland. Without the thymus, a person falls victim to multiple viral and fungal infections which the person is unable to fight off due to weak production of
lymphocytes (which destroy viruses and fungi). It is hideously disfiguring and inevitably fatal-usually at a very early age. See Rebecca H. Buckley, Immunodeficiency
Diseases, 268 JAMA 2797 (1992) .
.36 Id .
.37 See Scott & Patterson, supra note 9, at 566; Liskowsky, supra note 19, at
.3225.
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inherited diseases. 38 So far, only diabetes 39 and Parkinson's
Disease research have progressed to the human testing
stage. 40
IV. PRESIDENT BUSH'S MORATORIUM ON GOVERNMENT FUNDING FOR RESEARCH INVOLVING ELECTIVELY ABORTED FETUSES.

A. Beginning the Moratorium
In March 1988, the Assistant Secretary of Health issued a
moratorium on federal funding to the National Institute of
Health for research on fetal tissue obtained from induced abortions.41 In a letter refusing approval of the Public Health Service Act, President Bush carefully and clearly articulated his
stand on this issue. 42 He began by reiterating that the moratorium was not a ban on fetal tissue research altogether (the
moratorium did not affect the privately funded sector); nor was
it a ban on all federal funding of fetal tissue researchY He
reminded the House that the moratorium only affected federal
funding of research on tissue obtained from induced abortions.44
Funding for research using tissue obtained from spontaneous abortions or ectopic45 pregnancies was not affected. 46
Furthermore, he stated that quantities obtained from these
funded sources should be sufficient for the researchers'
needsY President Bush went on to say that the interests of
this nation would not be served through the federal funding of
research that was "promoting and legitimatizing abortion," and

38 Scott & Patterson, supra note 9, at 566.
39 George Archibald, NIH Skirts Ban on Transplants of Fetal Tissue, WASH.
TIMES, Jan. 6, 1992, at A7 (stating that the first unsuccessful human fetal pancreas transplant for diabetes was performed in 1939; the first successful (reduced daily insulin by 20%) transplantation was done in 1986).
40 Liskowsky, supra note 19, at 3225.
41 Nadler, supra note 35.
42 Message to the House of Representatives Returning Without Approval the
National Institute of Health Revitalization Amendments of 1992, 28 WEEKLY COMP.
PRES. Doc. 1132 (June 23, 1992) [Hereinafter Message to the House].
43 ld.
44 ld.
45 An ectopic pregnancy is one where the fetus grows outside the womb and
must be surgically removed. Glazer, supra note 31.
46 Message to the House, supra note 42.
47 ld.
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which is "morally repugnant" to many Americans. 48
Many doctors presented opinions to the House and Senate
to the effect that the moratorium imposed too heavy a restriction on the potential advancement of science based on an abstract possibility of swaying ambivalent mothers toward getting
an abortion. 49 They further argued that the regulations that
would be included in the Revitalization Amendment would be
sufficient to remove the "possibility of evils" associated with
tissue harvesting. 50
The proposed United States regulations were quite similar
to those of the United Kingdom and Mexico. They included
prohibitions on purchase of fetal tissue; solicitation of tissue
from an induced abortion when there is a specified donee and
the donor/donee are related, or when the soliciting person gives
valuable consideration for costs of the abortion; and altering of
timing, method, or procedure for termination solely for obtaining tissue. 51 The proposed regulations also include the following requirements: informed consent from the donor; consent to
the abortion prior to the request for consent for tissue donation;
full disclosure of any personal interest the physician may have
in the tissue; researchers can have no part in timing, method
or procedure for the abortion; and the donee must know the
tissue received is aborted or stillborn human tissue donated for
this purpose. 52
As proposed, the United States' regulations would be very
similar to those established in Mexico and Great Britain. Those
countries specify the need for informed consent of the donor,
obtained separately from the consent for the abortion, and in a
method more conducive to a non-prejudiced decision to
abort. 53 Mexico's statute in 1990 required the use of spontaneously aborted tissue only. 54 Great Britain and the United
States both concur that the method of abortion may not be
altered after consent to donate the fetus has been given. 55
48 ld.
49 138 CONG. REC. 84759 (daily ed. Apr. 2, 1992). As yet, neither side of
this issue has generated demographics or offered any other type of factual proof to
support their position.
50 ld. at 4759.
51 138 CONG. REC. H3340, at 3342 (daily ed. May 18, 1992) (reporting on
H.R. 2507).
52 ld. at 3342.
53 NEURAL TRANSPLANTATION 140 (Stephen B. Dunnett & Anders B. Jorklund
eds., 1992).
54 Madrazo et al., supra note 25.
55 See Code of Practice on the Use of Fetuses and Fetal Material in Research
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This avoids putting the mother in a higher level of risk caused
by different abortion procedures in order to retrieve usable
tissue. 56
Mexico's regulatio-ns are quite similar to those proposed for
the United States except they restrict tissue to spontaneously
aborted tissue only, 57 whereas neither the United States 58
nor the United Kingdom place any restriction on the cause of
the abortion. 59
Dr. Jay Moskowitz, then Associate Director for Science
Policy and Legislation at the National Institute of Health,
argued for the removal of restrictions on electively aborted
tissue because the use of spontaneously aborted tissue would
net a poorer quality tissue and an insufficient number of available fetuses. He claimed:
The cells and tissues from spontaneous abortions and ectopic
pregnancies are generally of poor quality because they (a)
may represent inherently abnormal tissue, (b) have been
subjected to diminished blood supply, (c) exist in a poor invivo environment, (d) may have been retained in the body for
five to eight weeks prior to explosion [sic]. The state of disintegration of these tissues is another factor affecting viabili-

ty.60
Drs. Freeman and Olanow added that bacteria associated
with spontaneously aborted fetuses transmitted to the fetus
through vaginal delivery of the fetus can increase the potential
for transplant related infections. 61

B.

Establishment and Purpose of a Fetal Tissue Bank

On May 19, 1992, President Bush, sensitive to the
researchers' need for fetal tissue, while true to his pro-life convictions, ordered the establishment of a fetal tissue bank. 62

and Treatment, FFMC (from Her Majesty's Stationery Office 1989) cited in FETAL
TISSUE TRANSPLANTS IN MEDICINE 331-32 (Robert G. Edwards ed., 1992); 138
CONG. REC. H3340, supra note 51, at 3342.
56 NEURAL TRANSPLANTATION 140 (Stephen B. Dunnett & Anders B. Jork!und
eds., 1992).
57 Madrazo et al., supra note 25.
58 138 CONG. REC. H3340, supra note 51.
59 Henderson et al., supra note 33.
60 Continuing Debates About Human Fetal Tissue, 1992 BIOLA W 2503 [hereinafter Continuing Debates].
61 Freeman & Olanow, supra note 30, at 900.
62 Exec. Order No. 12,806, 57 Fed. Reg. 21,589 (1992) [hereinafter Exec.
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With the establishment of the tissue bank, President Bush
tried to soften the impact of the moratorium by authorizing collection of fetal tissue obtained through spontaneous abortions
and ectopic pregnancies and by making this tissue available to
qualified researchers. 63 He also authorized development of "cell
lines" in accordance with the spontaneous abortion/ectopic
pregnancy limitations. 64 A "cell line" is the "capacity to clone,
or endlessly reproduce, certain fetal cells in a laboratory in
immortal ... lines."65

C.

Support for the Moratorium and a Fetal Tissue Bank

Louis W. Sullivan, as Secretary of the Department of
Health and Human Services, enumerated the "compelling reasons" for supporting the President's establishment of a fetal
tissue bank. 66 First, adequate tissue could be collected from
spontaneous abortions and ectopic pregnancies at six major
medical centers across the nation. Second, the administration's
estimate of the number of fetuses needed is a conservative one.
"Only 60 fetal tissue transplants have been conducted in the
last 30 years,"67 and according to the Bush estimate, 1000 usable fetal cadavers could be collected annually. 68 Finally, the
federal govemment already funds the National Institute of
Health's research in the alternative research avenues (cell lines
for one). 69
There are other reasons for banning the funding and the
use of electively aborted tissues. One argument is that federally
funded use of electively aborted fetuses legitimizes abortion.
This was a signal the Bush administration did not wish to
send. 70
Another argument against allowing the use of elective
abortions is that it could lead to the development of a "baby

Order 12,806]. This was not the first time a tissue bank had been established. In
1961 the NIH funded the Central Laboratory for Human Embryology at the University of Washington in Seattle. See Archibald, supra note 39, at A7.
63 Exec. Order 12,806, supra note 62, § 2.
64 Exec. Order 12,806, supra note 62, § 3.
65 Rorie Sherman, The Selling of Body Parts, NAT'L L.J., Dec. 7, 1987, at 1.
66 Louis W. Sullivan, Good Reasons for the Fetal Tissue Research Ban,
WASH. POST, Aug. 16, 1992, at C6.
67 ld.
68 Julianne Byrne, On Fetal Tissue, Bush Shows He's Pro-Death; Tissue
Bank Is Needed, N.Y. TIMES, July 14, 1992, at A24.
69 Sullivan, supra note 66.
70 Message to the House supra note 42. But see infra part IV.H.
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market" and pregnancies for abortions' sake. 71 Competition
and the prospect of monetary remuneration could encourage
doctors to use procedures with higher risk to the mother in
order to obtain usable fetuses for research. 72

D. Arguments Against the Moratorium and the Alleged Sufficiency of a Fetal Tissue Bank
Opponents of the ban agree that use of elective abortions
could result in a "baby market.'m They argue, however, that
this result would not be all bad. For now, a fetus does not qualify as a "baby." Like blood, a fetus is considered just a collection of cells. Sale of blood is not prohibited generally, so why
should the sale of fetuses be prohibited? 74 Opponents of the
ban argue further that the Bush position was hypocriticaL
They argued that there was already a "private market" for
fetuses tacitly sanctioned by the government as long as federal
funds were not involved. 75
Proponents of fetal tissue research argue that any "procedure" problem can be eliminated by regulations against altering the planned abortion procedure after permission to donate
the tissue has been obtained from the mother. 76 However,
growing interest in fetal tissue research will also increase the
availability of commercial incentives. 77 In fact, there is already a high demand for tissue collected, live "from abortions
performed in weeks 20 through 24." 78 Pro-choice proponents
claim that second and third trimester abortions are "unusual,"
but the Centers for Disease Control estimates that about
16,000 abortions a year are done after twenty weeks gestation. 79 Furthermore, at the Risk Management Seminar of the
National Abortion Federation's September 1992 seminar, ten
practitioners gave papers on performing second trimester abor-

71 See Sherman, supra note 65, at 32.
72 NEURAL TRANSPLANTATION, supra note 53, at 140.
73 !d. at 32.
74 Michael Schrage, Vision and Rational Discussion Needed in Fetal Tissue
Debate, WASH. POST, July 31, 1992, at F3.
75 ld. See also 138 CONG. REC. S4759, supra note 49 (Senator Adams reading a letter by Reverend Guy Walden into the record).
76 138 CONG. REC. 84759, supra note 49.
77 Douglas Turner, Ethics Issues Raised in Use of Fetal Tissue, BUFFALO
NEWS, June 14, 1993, at 3; see also, Roger W. Evans, Organ Procurement Expenditures and the Role of Financial Incentives, 269 JAMA 3113 (1993).
78 Turner, supra note 77, at 3.
79 !d.
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tions. 80 Dr. Martin Haskell's seminar included a procedure for
removing brain tissue from a fetus in a manner meant to "protect the skull and its contents until the last minute."81 This
seems an unnecessary concern unless the goal is actually obtaining usable fetal brain tissue.
It is also argued that President Bush's estimate on the
number of available fetuses, as well as the number of fetuses
needed, was an inaccurate one. They argued that spontaneously aborted tissue and ectopic pregnancies are argued to be
inherently infected or defective. 82 Electively (or surgically)
aborted fetuses are, as Dr. Bernadine Healy (then Director of
the National Institute of Health) said, "[a]pt to be uninfected
and more likely to be genetically normal."83 As the demand for
fetal tissue transplants increases as progress is made, the
bank's supplies will be inadequate to meet the demand. 84
Without federal funding many Parkinson's patients who
desired fetal tissue transplantation would not be able to obtain
it because of its tremendous cost. The government, under the
moratorium, does not "foot the bill" for these experimental
operations if electively aborted fetuses are used. 85 This argument, however, is premised on the assumption that researchers
will not be doing the operations unless electively aborted fetuses are provided.
Another unpersuasive argument is that the lack of federal
funding discourages colleges and hospitals from participating in
fetal tissue transplant research and thereby diminishes the
"brain pool" available for new research. 86 Again, the assumption is that researchers will use electively aborted fetuses or
not research at all.

E. Analysis of the Two Counter-Arguments
The arguments pertaining to demand and availability of
fetuses is unpersuasive. Future demand may increase, but until
it does-and a great deal depends on federal funding of such

80 !d.
81 !d.
82 Continumg Debates, supra note 60.
83 James Mason, Fetal Transplant Fallacies, WASH. TIMES, June 16, 1992, at
F3 (quoting Dr. Healy).
84 !d.
85 Gina Kolata, Evidence Found that Fetal Tissue Transplants Can Ease a
Brain Disease, N.Y. TIMES, May 7, 1992, at Bll.
86 !d.
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research-the bank's 1000 fetuses should suffice. Even if the
estimate of available fetuses was reduced by one-half, the .current need for fetal tissue could be met. 87 An odd contradiction
among the pro-choice and pro-federal funding arguments
arises. The proponents of lifting the ban claimed, as one of
their foremost arguments, that the ban would create a deficiency in available fetuses. Pro-choice advocates, who wanted the
lifting of the ban on federally funded fetal tissue research, also
want the ban on the French abortion pill RU 486 lifted. 88
Since RU 486 must be used before the eighth week of pregnancy, and harvesting the most usable tissue generally takes place
after the seventh week of gestation, it seems that the wide use
of RU 486 would significantly increase the deficit of available
fetuses claimed to be so detrimental to the advancement of
scientific research in this area.
The argument that some PD patients will be denied treatment without federal funding (due to the moratorium) has
more "teeth" than does the numbers argument. Five hundred
thousand people are estimated to be suffering from PD. 89 At
least one report places this amount as high as one million people. 90 As progress is made, if it is ever made, those desirous to
be participants in this research will also increase. It is quite
possible that the number of people desiring transplants could
exceed the number of fetuses obtained through spontaneous
abortions or ectopic pregnancies (especially since fetal tissue
research is not only done for PD ).
Although private funding can be used to transplant with
an electively aborted fetus, the cost of this procedure begins at
$30,000. 91 This cost is to the patient because insurance usually does not pay for experimental procedures. Private donations
can help, but only minimally. Dr. Eugene Redmond, neural
transplant program director at Yale University, said that if
federal funding were available, his program would do at least
one PD related transplant per month in contrast to the eleven

87 Byrne, supra note 68, at A57.
88 Kate Michelman & Marcy Wilder, The RU 486 Dilemma; Abortion Drug
Must Be Legal, NAT'L L.J., Sep. 7, 1992, at 13. See infra p. 193.
89 Schrage, supra note 74.
90 Dwight E.M. Angell & Hugh McCann, Fetal Tissue Research May Help
Victims of Parkinson's Disease, GANNETTE NEWS SERVICE, Feb. 9, 1993; see also
Lieberman et a!., supra note 6, at 1.
91 Glazer, supra note 31.
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operations done in three years on private funding. 92 The availability of this procedure to only those who can afford to pay
"throws a tremendous bias into the system."93 However, the
removal of the ban will not lessen the expense of the procedure,
it will merely shift the burden of paying for it onto the taxpayer. Even if the procedure becomes a "standard" one, there is no
evidence that the cost to patients or insurance companies will
lessen. In fact, the present trend of our health care system
demonstrates quite the reverse. Additionally, even if a national
health care plan is adopted, this procedure is probably too
costly and too infrequent to ever merit inclusion.
The allegation that the moratorium on federally funded
research (involving electively aborted fetuses) drains the "brain
pool" of competent researchers seems clearly a misleading one.
Although Dr. Eugene Redmond, Jr. said that "there ha[d] been
major private foundations and drug companies that otherwise
would have supported this research, but [didn't] because of the
moratorium;"94 and that now "researchers will have more security than they did with private funds," 95 there are alternate
research areas, whose funding was not, nor is it now, significantly reduced. The media and many anti-ban proponents kept
conveniently forgetting this fact and generally do not even
mention alternatives to federally funded fetal tissue research.
Paul Reiser, a professor of neurology with the University of
Florida, said that the moratorium caused "no standstill" in fetal
tissue research. 96 Using "private funds, medical societies and
other institutions," fetal tissue research has "flourished in dozens of states" these "past 4 years.'m Actually, several authors
raved about the "promise" and "tremendous progress" of fetal
tissue transplantation in treating PD, 98 when in reality even
the physicians conducting the research say that fetal tissue
transplants do not cure PD nor are they even considered a

92 !d.
93 Legislative and Other Developments in Human Fetal Tissue Transplantation Research, 1992 BIOLA W 2433, 2437 [hereinafter Legislative and Other Developments] (quoting Dr. Rohert Breeze).
94 Marlene Cimons & Thomas H. Maugh, II, After Five-Year Wait, Scientists
Are Set to Resume Research on Fetal Cells, L.A. TIMES, Jan. 26, 1993, at AS.

!d.
96 Eric Adler, Ban on Fundinp Ff'tal Tissue Research Seldom Stopped Work,
PHOENIX GAZJ.:TI'E, Jan. 23, 1993, at Al.
97 !d.
9R Kolata, supra note Rfi (quoting Dr. Olanow).
9fi
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successful long-term treatment. 99
While some of the arguments for using electively aborted
fetuses in research for Parkinson's are somewhat persuasive,
ultimately the decision hinges on the diminishment of the human being to a bundle of marketable goods. 100 The Pope, in
his 1993 Colorado speech, said we are developing "a spreading
anti-life mentality, an attitude of hostility to life in the
womb." 101 What will opponents to the ban argue as technology pushes back (toward conception) the age of viability for
fetuses? Are embryos conceived outside the womb, and then
"grown" outside the human body-maybe eventually grown to
full term in an artificial womb (an area of research currently in
progress) 102 considered babies? At what point? Currently,
there are no answers to these questions.

F.

General Arguments Against Fetal Tissue Use in Treating
Parkinson's Disease

During the congressional consideration of the Public
Health Service Act, opponents of Bush's moratorium argued
that to control fetal tissue research in any fashion was to sentence PD patients, like Senator Udall, to unnecessary suffering. 103 Yet, none of the studies have concluded that their procedures were or were not successful. Dr. Olanow himself said
that the transplant-treated patients "are by no means
cured." 104
Swedish researcher Ollie Lindvall went even further. He
said, "[a]lthough animal experimental data are very promising
and clinical trials have given encouraging results, it must be
underscored that there exists at present no treatment for

99 Mason, supra note 83 (quoting Lindvall).
100 It is quite different to use a fetus which would have died anyway, than
to use one that is deliberately killed and then purchased. This is analogous to
murdering someone for their kidneys. Though there are current laws on the sale of
body parts in the United States (see infra note 117), the selling of body parts
world-wide is not unheard of-especially in India and China. See Barbaric Trade:
Harvesting Organs of Executed Prisoners, GAZETIE, March 30, 1993, at A2; Risks to
Buying Kidneys, STRAITS TIMES, May 13, 1992, at 3.
101 Martin Walker, Pope Tones Down Abortion Speech, GUARDIAN, Aug. 16,
1993, at 6.
102 William A. Check, Margery Shaw, MD. JD: Twice Counselor, 247 JAMA
2R84, 2890 (1982) (quoting Dr. Shaw as saying that an artificial womb may be
possible in the future).
103 138 CONG. REC. S4759, supra note 49 (quoting Senator Domenici).
104 Kalata, supra note 85.
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Parkinson's Disease based on intracerebral transplantation."105
As yet, there has not even been a consensus on the several
important issues, including the brain region for implantation,
the best surgical technique to use, the need for immunosuppressants, the best fetal age for harvesting tissue, the type of
tissue to use, the clinical usefulness, or any long term results.106 Until such consensus can be made, or a definitive
long-term benefit is attained, there seems no reason to focus
exclusively (or extensively) on fetal tissue research, especially
when there are alternate areas of research just as promising
which do not require fetal tissue and therefore do not involve
the abortion issue. 107
It is the moral issue of abortion which generally caused
Bush to implement the moratorium. 108 This alleged need for
fetal brain tissue puts at issue the very concept of a fetus as
non-living-not worth the sacrifice of a woman's privacy. One
recent article in the ''Washington Post" even listed "spontaneous sex, luxury, extended travel, higher education, unbroken
career paths, choosing a different father, and limiting family
size" as "perks" of abortion. 109 This seems to put "creating/terminating life" right below waiting for the telephone man,
and just above a bad haircut on the scale of "inconveniences."
Yet, as Paul Panuli and Paul O'Connor put it, "[o]ne simply
cannot have it both ways. The first trimester fetus cannot be
simultaneously a 'blob' and a human being with a specialized
brain structure suitable for transplant." 110 If "human" fetal
tissue is so superior to other mammalian tissue, m "how can
it be denied ... that the child in the womb ... is fully
'human' ... and entitled to full protection of the law." 112
This subordination of fetal life to what seems an increasing
tenacity to live at all costs would combine to encourage, or at

105 Mason, supra note 83.
106 Curt R. Freed et al., Transplantation of Human Fetal Dopamine Cells for
Parkinson's Disease: Results at 1 Year, 47 ARcH. NEUROL. 505 (1990).
107 For example, cell lines, genetic engineering, alternate surgeries, new
drugs.
108 Message to the House, supra note 42.
109 Carolyn Hax, No Birth, No Pangs; For Many Young Women, Abortion is a
Given, WASH. POST, March 21, 1993, at Cl.
110 Legislative and Other Developments, supra note 93, at 2436 (quoting Paul
Panuli and Paul O'Connor).
111 Turner, supra note 77.
112 ld.
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least justify for some, abortion. Though proponents of the Public Health Service Act argued that their proposed regulations
would prevent encouragement of abortion by waiting to ask for
donation of a fetus until after the consent to abort was given, 113 they fail to consider the wide publicity associated with
any abortion issue. Pro-Life and anti-abortion supporters air all
the ramifications of their opponent's proposals openly to the
press as often and as loudly as possible. It seems impossible,
therefore, to believe that the majority of American women will
be ignorant of the possible use of an aborted fetus for medical
research. Waiting to ask for consent until after the abortion
decision is made, is rather like a judge requesting the jury to
disregard a statement made in court by a witness or counsel.
Legally it may work, but realistically it is very hard to put
those thoughts out of one's mind when making the final decision.
Proponents of the use of federally-funded fetal tissue research also failed to adequately respond to the challenge that
use of electively aborted fetuses can lead to baby selling. Superficially, doctors and legislators say the regulations preventing
the donor from receiving monetary gain would sufficiently exorcise this particular problem 114 (if in fact it even is one). But
donors are not the only ones susceptible to the lure of a potentially lucrative market. Even now, legislatures and courts are
faced with deciding who is entitled to monetary remuneration
for patented "cell lines" 115 and who is the "owner" of fetuses
used in surrogacy cases. 116 Until recently, research labs and
doctors/scientists were the only ones receiving the compensation from research done with someone else's body parts. 117 In
fact, the growing concern over the conflicting interests of researchers and commercial investors has lead to the adoption of

113 138 CoNe;. REC. 84 759, supra note 49 (quoting Senators McCain and
Riegle respectively).
114 138 CONG. REC. S4759, supra note 49 (quoting Senator Dodd).
115 Moore v. Regents of Univ. of Cal., 271 Cal. Rptr. 146 (Ct. App. 1990),
cert. denied, 1991 U.S. LEXIS 1723 (1991).
116 In Re Baby M1, 525 A.2d 1128 (N.J. Super. Ct. Ch. Div. 1987), rev'd, 537
A.2d 1227 (N.J. 1988).
117 Many states have legislation making it a crime to buy or sell human organs within their jurisdictions. See, e.g., CAL. PENAL CODE § 367f (Deering 1992);
FLA. STAT. ch. 873.01 (1991); LA. REV. STAT. ANN. § 14:101.1 (West 1992); MD.
CODE ANN., HEALTH-GEN. § 5-408 (1991); NEV. REV. STAT. ANN. § 201.460 (Michie
1991); S.D. CODIFIED LAWS ANN. § 34-26-44 (1992); TEX. PENAL CODE ANN. § 48.02
(West 1992).
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"disclosure" statements. 118 For example, some universities
require "scientists to disclose not only who pays for their work,
but whether they have any outside income from industrial or
corporate sources, or any stock in companies whose products
they test." 119 Medical journals are also starting to list the financial backers of each study, and "whether the private sponsor ... was involved in collecting data, analyzing it or approving the final article." 120
Finally, there is a strong presumption that with the success of fetal tissue transplantation, if any, the need for fetal
tissue as a "curative" will be supplanted to that of a "therapy". 121 This could also lead to an astronomical leap in the
amount of fetal tissue required per year. As Michael Schrage
put it, "Fetal transplant surgery could become more prevalent
than heart surgery." 122 With this increased demand (with
over 500,000 Parkinson's patients; 123 750,000 diabetics; 124
and 2,000,000 or more Alzheimer patients 125 the potential is
great) could come the increased pressure from families demanding to provide tissue for their ailing family members. 126
With the ease in obtaining a first-trimester abortion, the possibility of allowing families to conceive in order to abort and
donate tissue to a family member is real. 127 Although proponents say they could "regulate" so as to avoid this possibility,
the inconsistency of forbidding directed donations of fetal tissue, when directed donations of other body parts is allowed, is
already being challenged. 128
Assuming that a fetus is indeed a life, using fetal transplantation as a therapy would mean that instead of a "life for a

118 Sheryl Stolberg, Funding Science-For a Pnce; As Public Money Dnes Up,
Medical Researchers Must Turn to Industry for Help. Private Backing Creates Some
Controverstal Partnerships, Raises Fears of Commercialism. Conflict of Interest, L.A.
TIMES, June 8, 1993, at Al.
119 Id.
120 Id.
121 Schrage, supra note 74.
122 Id.
123 Id.
124 Id.
125 Id.
126 Id.
127 Transplant from Baby for Teen Sister Goes Well, CHI. TRIB., June 5, 1991,
at ClO (relating the case of a couple's deliberate conception of a child for the possible use of it as a bone marrow donor (if the blood type was compatible) for their
older daughter).
128 Schrage, supra note 74.
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life" type justification doctors would be dealing with a "life for a
more comfortable life." When should the quality of one life be
considered superior to the life of another in and of itself?
Where would the "killing" stop? Quality of life arguments tend
to eventually lead to a euthanasia argument. Are we, as a
society, prepared for that kind of mentality to predominate in
the medical profession?

G. Plausible Alternatives
There are some who believe all the agonizing over the
elective abortion issue is unnecessary; that the combination of
alternate research areas and fetal tissue research (limited to
spontaneously aborted or ectopic fetuses) gives adequate coverage to the research into the treatment of PD. Robert H. Baker,
of Vienna, cites the studies at the University of Toronto and
Hahnemann University in Philadelphia as examples of alternate areas of research. 129 Both universities "have had significantly positive results (in PD patients) from using a substance
derived from mammalian brain cells to stem damage and
stimulate brain cell repair in humans." 130 Baker said this line
of research is "at least as promising as using human fetal
tissue." 131
Dr. Robert J. White, after reviewing the minimal improvement of Parkinson's patients treated with fetal tissue transplants, urges the use of biotechnological genetic engineering
(cell lines for one) to treat neurological disease without the use
of fetal tissue. 132 Recent developments in genetic engineering
have allowed scientists to "grow fetal brain cells in the lab" and
insert "genes into the cells to make all sorts of growth-stimulating chemicals" which, according to Dr. Eugene Major of the
National Institute of Neurological Disorders and Stroke, "will
make it unnecessary to use tissue from aborted fetuses." 133
Joseph Rogers, of the Sun Health Institute for
Biogerontology Research Center, "is trying to trick brain cells
from recently deceased adults into believing they are fetus129 Robert H. Baker, We Don't Have to Fight over Fetal Tissue, WASH. POST,
June 22, 1992, at A16.
130 ld.
131 ld. But see Turner, supra note 77.
132 Robert J. White, On Fetal Tissue; The Myth of a Transplant Cure, N.Y.
TIMES, Aug. 15, 1992, § 1, at 18.
133 Tim Friend, Living Secrets of Fetal Tissue, USA TODAY, May 18, 1993, at
7D.
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es." 134 The process is still a long way from being a reality and
is extremely complex. Scientists will take these live, dopamine
producing cells and grow them in a test tube, trick them into
multiplying as "fetal cells," and then trick them again to stop
multiplying when there is enough replacement tissue. 135 If
the cells do not stop multiplying, the transplant would, in effect, become a "tumor" growing "uncontrollably." 136
There are also researchers focusing on drug therapy for PD
patients. None have yet "alter[ed] the underlying disease process," as Dr. Laurence Golbe said, 137 but "some believe it is
only a matter of time before medication will stop the disease in
its tracks." 138
One of the newest drugs tested, Deprenyl, has been found
to delay the need for L-dopa medication for about nine
months. 139 Since L-dopa medications have a limited usefulness, 140"any delay in onset of this treatment is generally considered a positive step." 141
Dr. Ira Shoulson, of the University of Rochester, says his
drug research includes "antioxidants that help protect brain
cells; growth factors that could work at protecting dopamine
cells; and drugs that block glutamate, a brain chemical thought
to excite cell death." 142 Dr. Shoulson also adds that drug testing has recently begun in conjunction with a cloned gene-a
dopamine transporter. 143 This phase of testing is "looking for
drugs that inhibit, or block, the gene," and according to Dr.
Shoulson, "in animals, it prevents the disorder." 144
There has also been a "resurgence" in two ablative surgical
procedures, which do not require the use of fetal tissue and
which originally were used in the 1950s. 145 Because of the
breakthrough in "the theory of the mechanism of brain dys-

1:~4 Lori Baker, Researcher Seeks Parkinson's Cure; "Like Science Fiction" but
Could Help Many, ARIZ. REPUBLIC, July 28, 1993, at 5.
135 ld.
136 ld.
137 Jamie Talan, Drug for Parkinson's Puts Off Use of Stronger Medication,
Report Says, NEWSDAY, Jan. 26, 1993, at 61.
1:18 ld.
139 ld.
140 See supra note 15 and accompanying text.
141 Talan, supra note 137, at 61.
142 ld.
143 ld.
144 ld.
145 Fazzini, supra note 17, at 1, 4.
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function underlining Parkinson's Disease," surgeons now are
retesting these procedures, putting small incisions in "circuitry"
gone awry due to low dopamine levels. 146
The pallidotomy (incision in the globus pallidus) is more
effective in reduction of slow movement problems than in tremor reduction, but it does offer an immediate improvement, and
eventually, a "complete resolution" of the dyskinesia (defect in
voluntary movement) caused by the drug therapy (actual drug
requirements remain about the same). 147 Twenty-two
pallidotomies have been done "without side effects." All the
pallidotomy subjects have had a fifty-seven percent improvement during the nine months they have been studied. 148 This
is better than the average of the last two Swedish fetal tissue
transplantations (at forty-seven and fifty-nine percent improvement).149 Furthermore, fetal transplants do not result in a decrease of dyskinesia as does a pallidotomy. 150
The thalamotomy (an incision in the thalamus) has shown
a ninety-eight percent reduction of severe tremor and also
resolves dyskinesia caused by drug therapy. 151 However, it
also tends to lead to "loss of muscle tone, balance impairment,
and speech impairment." 152
These alternate sources of treatment materials, with fetuses obtained via spontaneous abortion and ectopic pregnancies
(already argued as sufficient in and of itself), and combined
with the privately funded, electively aborted fetuses, should be
sufficient to yield adequate experimental material without
having to expand the federal funding to electively aborted fetuses.

H.

Fetal Tissue Research Under Clinton

On November 3, 1992, Bill Clinton was elected President of
the United States. Within days of his inauguration Clinton did
what Congress had been unable to do despite months of trying:
He removed the moratorium on federal funding of research
involving electively aborted fetuses. 153
146
147
148
149
150
151
152
153

!d. at 1.
!d. at 4.
!d.
!d.
!d.
!d.
!d.
Talan, supra note 137, at 61.
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Unfortunately, this action came as no surprise to pro-life,
anti-abortion supporters. Clinton's political stance on abortion
during the campaign was pro-choice. 154 Almost immediately
after his election, Clinton's aides were announcing the probable
demise of the moratorium. 155 Democrats (including Edward
Kennedy and Richard A. Gephardt) as well as the National
Abortion Rights Action League (NARAL) expected Clinton to
honor his promise to free the country from restrictions to a
woman's right to choose: restrictions on abortions. 156 Kate
Michelman, president of NARAL, explicitly enumerated the
things she and the "abortion-rights voters [who] elected"
Clinton expected him to do: (1) lift the ban on federally funded
research involving elective abortions; (2) lift the gag rule imposed on family planning clinics; (3) lift the ban on RU 486 (the
abortion pill); (4) codify abortion rights (Freedom of Choice
Act); and, (5) include abortion in any national health care
plan.I57
If Clinton was to avoid Bush's "read my lips" mistake, he
had to take swift action in this area. On January 22, 1993
President Clinton did indeed lift the moratorium on federal
funding of fetal tissue research using elective abortions, 158
and in May of 1993, a bill authorizing $6 billion in funding to
the National Institute of Health was passed by both the House
and Senate. 159 Wanda Franz, President of the National Right
to Life Committee, said recently that with this the President
has put "the federal govemment in the business of promoting
the use of abortion as birth control." 160
V.

CONCLUSION

It is unrealistic to think that "potential good" associated
with fetal tissue research will not sway abortion decisions.
Nearly every fetal tissue article written mentions this aspect,
so persuasion is within the realm of possible ramifications.

154 Robert S. Boyd, Abortion Restrictions Out; Clinton Keeps Promise, TIMESJan. 23, 199::l, at Al.
155 Elizabeth Neuffer, Bill Vetoed by Bush Could Serve as Clinton's Blueprint,
BOSTON GLOBE, Nov. 5, 1992, at 27.
156 !d.
157 !d.
158 Boyd, supra note 154.
159 Fetal Tissue: House Approves NIH Authorization Bill, Abortion Report,
May 26, 1993.
160 Boyd, supra note 154.
PICAYUNE,
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Although I am decidely pro-life, thorough thought and research
were required for me to decide that using electively aborted
fetal tissue-even to save loved ones some anguish-was
wrong. If I can question, so can those who find themselves in
the uncomfortable position of being undesireably pregnant,
since they also have a strong reason to rationalize their decision to abort.
Limiting the psuedopodic-spread of aborted fetal tissue
research, and regulating its commercialization once allowed,
could prove a formidable task, especially as awareness of the
potential value of fetal tissue spreads. Combining the power to
persuade, and the potential of regulatory problems with the inconsistent results of present fetal transplant testing, leads to
the conclusion that failure to limit use in this area of research
can only be looked upon as the science fiction movie monster
turned loose-bent on the destruction (however insidiously) of
the morals of the American people.

Billye D. Baird
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APPENDIX
Executive Order 12,806
Establishment of a FETAL TISSUE Bank
May 19, 1992
By the authority vested in me as President by the Constitution and the laws of the United States of America, and in
order to provide a source of human tissue to develop treatments and research methods for various diseases, it is hereby
ordered as follows:
Section 1. Establishment of a FETAL TISSUE Bank. The
Secretary of Health and Human Services ("Secretary") shall
establish a human FETAL TISSUE bank. The FETAL TISSUE
in the bank shall be obtained exclusively from ectopic pregnancies and spontaneous abortions.
Section 2. Procedures. The Secretary shall establish procedures for making tissue from the bank available for meritorious
research projects selected through an appropriate peer review
process. The Secretary shall include in the bank a registry of
physicians and hospitals interested in using the tissue from the
bank to further specific medical objectives.
Section 3. Policies. The Secretary shall develop human
fetal cell lines in a manner consistent with current policy and
ensure that the actions directed by sections 2 and 3 of this
order are carried out in accordance with all other applicable
legal requirements related to FETAL TISSUE.
Section 4. Report. The Secretary shall report his progress
in carrying out this order to the President on or before December 31, 1992.
GEORGE BUSH
THE WHITE HOUSE,
May 19, 1992
Exec. Order No. 12,806, 57 FR 21589, 1992 WL 193236 (Pres.)

